Tessera Therapeutics announced permanent layoffs affecting roughly 35% of staff (about 90 employees) as it shifts focus to a gene‑editing collaboration with Regeneron and prioritizes an in‑vivo AATD program supported by a $150 million Regeneron investment. Tessera said the restructuring will preserve clinical advancement capacity and leave core CAR‑T gene‑writing efforts intact. Separately, Lyra Therapeutics suspended further development of its implanted CRS drug LYR‑210 and laid off its remaining employees, retaining only CEO and CFO as consultants while pursuing strategic alternatives. Lyra cited limited cash runway and a board decision after a strategic review. Both moves reflect ongoing portfolio prioritization in biopharma: companies are trimming programs and workforces to extend runway and focus on higher‑value partnerships or to prepare assets for out‑licensing or sale.